CBMG has $465,000,000 market cap and describes itslf as follows:
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit:
Press release this morning:
10:00 AM EDT, 06/05/2015 (MT Newswires) -- Cellular Biomedicine Group(CBMG) shares are higher on Friday after research was published on the use of human adipose-derived progenitor cells (haMPCs) to treat knee osteoarthritis (KOA) in a peer-reviewed scientific journal.
The publication, titled "Human Adipose-Derived Mesenchymal Progenitor Cells Engraft into Rabbit Articular Cartilage," appears online in the May edition of the International Journal of Molecular Sciences.
"We are very pleased to see this important pre-clinical data published on one of the applications of our regenerative medicine stem cell platform," said company CEO Dr. William (Wei) Cao. "The data bolsters our belief in the effectiveness of our lead product candidate, ReJoin, an haMPC therapy in treating KOA and promoting the regeneration of cartilage."
The cell therapy company is currently running a Phase IIb clinical trial of its ReJoin therapy for knee osteoarthritis and previously released positive 24-week interim data. It expects to complete Phase IIb 12-month patient follow-up by the fourth quarter of 2015.